Trial Profile
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiretroviral Activity of MK-1439 in HIV-1 Infected Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Doravirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 13 Sep 2015 Results published in the AIDS.
- 05 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
- 15 May 2012 Actual end date (April 2012) added as reported by ClinicalTrials.gov.